Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 476.51% is 2922% above its 5-year average of -16.88%, near the high end of its 5-year range (-424.61%–476.51%).
As of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 476.51%.
RETURN ON EQUITY (ROE)
476.51%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
13.59%
RETURN ON EQUITY (ROE) AVG 5Y
-16.88%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+3405.51%
CURRENT VS 5Y AVG
+2922.18%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.51%
median of 459 covered companies
CURRENT VS SECTOR MEDIAN
+1337.37%
vs the sector median at left
Amneal Pharmaceuticals, Inc.
Market Cap
$6.52B
Return on Equity (ROE)
476.51%
TTM Avg
N/A
3Y Avg
13.59%
5Y Avg
-16.88%
Market Cap
$6.53B
Return on Equity (ROE)
20.99%
TTM Avg
25.07%
3Y Avg
24.12%
5Y Avg
13.08%
Market Cap
$6.66B
Return on Equity (ROE)
-43.83%
TTM Avg
25.09%
3Y Avg
5.57%
5Y Avg
0.40%
Market Cap
$6.72B
Return on Equity (ROE)
33.11%
TTM Avg
27.03%
3Y Avg
27.48%
5Y Avg
31.41%
Market Cap
$6.24B
Return on Equity (ROE)
-39.33%
TTM Avg
-54.18%
3Y Avg
-65.89%
5Y Avg
-59.69%
Market Cap
$6.84B
Return on Equity (ROE)
-73.19%
TTM Avg
-58.90%
3Y Avg
-54.50%
5Y Avg
-46.46%
Market Cap
$6.11B
Return on Equity (ROE)
20.38%
TTM Avg
5.87%
3Y Avg
3.40%
5Y Avg
3.36%
Market Cap
$6.01B
Return on Equity (ROE)
-21.80%
TTM Avg
-16.70%
3Y Avg
-22.00%
5Y Avg
-23.98%
Market Cap
$7.03B
Return on Equity (ROE)
3.66%
TTM Avg
19.17%
3Y Avg
13.19%
5Y Avg
6.34%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.52B | 476.51% | N/A | 13.59% | -16.88% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.53B | 20.99% | 25.07% | 24.12% | 13.08% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.66B | -43.83% | 25.09% | 5.57% | 0.40% |
| Chemed Corporation (CHE)vs › | $6.72B | 33.11% | 27.03% | 27.48% | 31.41% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $6.24B | -39.33% | -54.18% | -65.89% | -59.69% |
| Immunovant, Inc. (IMVT)vs › | $6.84B | -73.19% | -58.90% | -54.50% | -46.46% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.11B | 20.38% | 5.87% | 3.40% | 3.36% |
| CG Oncology Inc. (CGON)vs › | $6.01B | -21.80% | -16.70% | -22.00% | -23.98% |
| Alkermes plc (ALKS)vs › | $7.03B | 3.66% | 19.17% | 13.19% | 6.34% |
| GRAIL Inc. (GRAL)vs › | $7.07B | -15.40% | -48.41% | -63.30% | -53.67% |
ROE
476.5%
ROA
4.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 476.51% |
| 2023-12-31 | -424.61% |
| 2023-09-30 | 3.12% |
| 2023-06-30 | -0.64% |
| 2023-03-31 | -45.78% |
| 2022-12-31 | -43.56% |
| 2022-09-30 | -44.38% |
| 2022-06-30 | -47.65% |
| 2022-03-31 | 0.45% |
| 2021-12-31 | 2.95% |
| 2021-09-30 | 3.98% |
| 2021-06-30 | 2.67% |
| 2021-03-31 | -5.36% |
| 2020-12-31 | 30.03% |
| 2020-09-30 | 20.58% |
| 2020-06-30 | -63.42% |
| 2020-03-31 | -62.49% |
| 2019-12-31 | -155.99% |
| 2019-09-30 | -85.55% |
| 2019-06-30 | -14.49% |
| 2019-03-31 | -57.00% |
| 2018-12-31 | -18.93% |
| 2018-09-30 | -19.83% |
| 2018-06-30 | -16.09% |
